None listed
Conditions
Brief summary
2 randomised controlled trials have demonstrated the safety and efficacy of cabergoline to limit the development of ovarian hyperstimulation syndrome (OHSS) in women at risk of this condition undergoing IVF treatment. This prospective observational study aims to look at the incidence of the development of the condition and any side-effects caused by the administration of cabergoline by women at risk of OHSS.
Interventions
In an IVF cycle oral cabergoline tablets 0.5mg per day will be taken from the day of initiation of follicular maturation by the sub-cutaneous injection of human chorionic gonadotrophin (HCG) prior to egg collection for a total of seven days. Despite egg collection and their fertilisation by their partner's sperm, embryos will be frozen and no fresh embryo transfer will be performed as these patients are at risk of OHSS. This is a 3 year observational study of all patients at risk of OHSS. Patien
In an IVF cycle oral cabergoline tablets 0.5mg per day will be taken from the day of initiation of follicular maturation by the sub-cutaneous injection of human chorionic gonadotrophin (HCG) prior to egg collection for a total of seven days. Despite egg collection and their fertilisation by their partner's sperm, embryos will be frozen and no fresh embryo transfer will be performed as these patients are at risk of OHSS. This is a 3 year observational study of all patients at risk of OHSS. Patients will only take the cabergoline as described if they are considered at risk of OHSS during their IVF cycle.
Sponsors
Fertility Specialists of Western Australia
Eligibility
Sex/Gender
All
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Patients whose oestradiol level is >15,000 pmol/l, or more than 20 follicles on ultrasound examination prior to the day of HCG trigger
Exclusion criteria
Patients with a significant concurrent medical illness or a contraindication to the administration of cabergoline.
Outcome results
None listed